Tuis207940 • KRX
add
Samsung Biologics Co Ltd
Vorige sluiting
₩1 585 000,00
Dagwisseling
₩1 551 000,00 - ₩1 631 000,00
Jaarwisseling
₩982 000,00 - ₩1 987 000,00
Markkapitalisasie
71,94 bn KRW
Gemiddelde volume
50,08 k
P/V-verhouding
41,95
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,45 bn | 52,94% |
Bedryfskoste | — | — |
Netto inkomste | — | — |
Netto winsgrens | — | — |
Wins per aandeel | 8,72 k | 25,60% |
EBITDA | — | — |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,46 bn | 12,13% |
Totale bates | 11,06 bn | -36,20% |
Totale aanspreeklikheid | 3,61 bn | -43,88% |
Totale ekwiteit | 7,45 bn | — |
Uitstaande aandele | 54,52 m | — |
Prys om te bespreek | 11,60 | — |
Opbrengs op bates | — | — |
Opbrengs op kapitaal | — | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | — | — |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
HUB
Gestig
2011
Webwerf
Werknemers
5 195
